Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors

Background Lanreotide is a long-acting somatostatin analog with demonstrated efficacy against enteropancreatic neuroendocrine tumor (NET) in the phase III (CLARINET) study. Materials and Methods In this single-arm study, Japanese patients with grade (G) 1/G2 NET received lanreotide (120 mg/4 weeks)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Tetsuhide, Honma, Yoshitaka, Hijioka, Susumu, Kudo, Atsushi, Fukutomi, Akira, Nozaki, Akira, Kimura, Yasutoshi, Motoi, Fuyuhiko, Isayama, Hiroyuki, Komoto, Izumi, Hisamatsu, Seiichi, Nakajima, Akihiro, Shimatsu, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502055/
https://www.ncbi.nlm.nih.gov/pubmed/28470558
http://dx.doi.org/10.1007/s10637-017-0466-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502055/
https://www.ncbi.nlm.nih.gov/pubmed/28470558
http://dx.doi.org/10.1007/s10637-017-0466-8

Ejemplares similares